CheckMyRecalls

10,013 recalls · updated 20 Nov 2026

Lupin Pharmaceuticals Inc. recalls Ganirelix Acetate Injection

Read the official FDA notice

Published
17 Dec 2025
Units affected
32736 vials
Agency
FDA
Country
United States

The hazard

Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Ganirelix Acetate Injection, 250 mcg/0.5mL, Single-dose Sterile Prefilled Syringe, 27 gauge by 1/2' needle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, United States, Manufactured by: Lupin Limited, Nagpur - 441108, INDIA, NDC 70748-274-01

Brand / company
Lupin Pharmaceuticals Inc.
Codes / lots
Lot #: WB00006, Exp 12/31/2026
Distribution
FL, MA, MI & OH
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 17 Dec 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.